Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.
US FDA finds control lapses at Catalent plant being sold to Novo
U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line,...
Novo Nordisk acquisition of Catalent production sensible, analysts say
Novo Nordisk (NYSE:NVO)'s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts say, and will help meet demand for its flagship weight ...
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...
Why Catalent Stock Soared Today
The pharmaceuticals manufacturing leader is being acquired by Novo Holdings. The transaction should close toward the end of 2024.
Novo Holdings Buyout Sends Catalent Stock Surging
The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11....
Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal
Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.
Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk
Catalent (NYSE: CTLT ) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE: NVO ) parent Novo Holdings for $16.5 billion. The transaction will have Novo...
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.
Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder
Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)'s controlling shareholder was to buy the firm for US$16.5 billi...
Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk
Novo Holdings will acquire Catalent for $63.50 a share in cash.
Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity
Novo Holdings, the holding company of Novo Nordisk , will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-lo...
Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion
Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's c...
Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo
Novo Nordisk's CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent's Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boo...
Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release fin...
Related Companies